3. Indian Biotech Products & Services: The Indian Biotech business stands at US$150 m today... … and is expected to be $ 750 m by 2005 and $1500 m by 2007… Bio-forecast #3 $ 150 $ 100 $ 150 $ 350 $1500m $750m $150m 2002 2005 2007 R&D Products & Services Ag Biotech Industrial Biotech Medical Biotech
4. Achievements ~ 50 Biotech PCT Patents have been filed in India ~ 20 r-DNA product clinical trials are on-going in India ~ 10 r-DNA products have been approved in India There are 6 r-DNA products being manufactured in India (Hep B, Interferon, GCSF, EPO, SK, BT cotton) There are 6 companies manufacturing recombinant vaccines There are 2 companies that will manufacture r-Human Insulin There are 2 companies developing Monoclonal Antibodies There are ~25 companies marketing Biotech products #4
5. New Delhi Pune Chennai Bangalore Hyderabad CCMB BHARAT BIOTECH SHANTHA BIOTECH DRL BIOLOGICAL E KNOWLEDGE PARK S-P BIOTECH PARK TCS ANNA UNIVERSITY MADURAI KAMARAJ UNIVERSITY SPIC PUNE UNIVERSITY ALFA LAVAL PRAJ INDUSTRIES SERUM INSTITUTE WOCKHARDT MIDC BIOTECH PARK IISC NCBS JNCASR IBAB ASTRA ZENENCA AURIGENE AVESTHAGEN BANGALORE GENEI BIOCON, SYNGENE GANGAGEN JUBILANT BIOSYS METAHELIX SARTORIUS STRAND GENOMICS BIOTECH PARK CROs: CLINIGENE, CLINITEC, LOTUS LABS DBT NII CBT DABUR GENOMED PANACEA BIOTECH JUBILANT Bio-clusters #5
15. India’s well developed fermentation and purification skills are being leveraged to a globally competitive bioprocessing platform... Bio-Processes in India #15 Biocon Shantha Biotech Serum Institute Shantha Biotech Bharat Biotech Wockhardt Panacea Biotech Dr. Reddy’s VACCINES RECOMBINANT THERAPEUTICS MONOCLONAL ANTIBODIES Biocon Wockhardt Dr. Reddy’s Shantha Biotech Bharat Biotech Hep B, Combi-vaccines Rabies, Leprosy Human Insulin, EPO, GCSF, SK, HGH, Interferon 2B Enti-EGF & others
16.
17.
18.
19. India is fast emerging as the hotbed of clinical research. One new CRO is being created every month... #19 CLINICAL DEVELOPMENT Siro Clinpharm Clinigene Quintiles Synchron Pfizer Clintec Covance Eli Lilly Novartis AstraZeneca Quintiles GSK Pfizer Novartis Eli Lilly DiagnoSearch Clinworld Infotech NEW DRUG TESTING BIO STUDIES BIOMETRICS/ DATA MANAGEMENT SITE MANAGEMENT Lambda Clinigene Lotus Labs Vimta Labs Apothecaries Synchron Wellquest Neemans
20. ``India is an attractive destination for clinical trials due to speed of patient enrollment and the quality of investigators.” Pawel Dyras V.P. Clintec "We have 17 large and small clinical trials in Phase II & III ongoing in India. ” Rajiv Gulati, Eli Lilly, India “ Folks at Biocon’s Syngene were certainly as fast as folks elsewhere, had a higher success rate and were almost an order of magnitude less expensive.” Peter Cohan, V.P. Discovery, SYMY “ It was the availability of high quality scientific talent and not the lower operational costs that led us to invest in a $40 million R&D centre at Bangalore.” Sir Tom McKillop, CEO AstraZeneca #20 Quotes
![Biotech Growth in India ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],#2](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)